Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. develops recombinant spider silk materials using genetically engineered silkworms that produce spider silk proteins. The company is focused on scaling these fibers for technical textiles and other advanced-material applications, while still operating at an early commercial stage with limited revenue and ongoing funding needs.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueGenetically engineered silk fibers produced from silkworms for advanced material uses.
Fiber-based materials intended for performance apparel, workwear, filtration, and composites.
Internal and collaborative R&D to improve fiber robustness and develop new materials.
Customers
The company’s target customers are textile, materials, and biotechnology partners that can commercialize spider silk-based fibers in finished products. End markets mentioned in filings include performance apparel, workwear, filtration, luxury fashion, flexible composites, medical implants, and cosmetics, with demand driven by interest in novel high-strength biomaterials.
Buy or co-develop spider silk fibers for performance apparel, workwear, and fashion products because of the material's strength and novelty.
Use the fibers in flexible composites and other advanced material applications where high strength-to-weight properties matter.
Work with the company on R&D, product testing, and platform development to expand material capabilities.
Potential buyers for spider silk-based materials in filtration and other niche industrial uses.
Strategy
Management is focused on scaling commercial production of recombinant spider silk while improving the robustness of its fiber lines. The company also wants to broaden commercialization through partnerships, collaborative R&D, and potential acquisitions, but near-term execution is constrained by limited cash and the need for additional financing.
The company needs larger, more reliable output before it can convert technical progress into meaningful sales.
Partnerships can provide manufacturing, marketing, and market access without requiring the company to build everything itself.
The company has insufficient cash to execute its plan and must fund operations through debt, equity, or strategic transactions.
Geography
The company is headquartered in the United States but has emphasized expansion of overseas production operations, including local contractors, cooperatives, and additional direct staff. Its business model depends on international manufacturing and collaboration because commercial-scale spider silk production requires specialized rearing and processing capabilities that may be built outside the U.S.
Risks
Kraig Biocraft is an early-stage development company with substantial going-concern risk because cash resources are insufficient to fund its business plan. Execution risk is high: the company must scale production, prove commercial demand, and secure financing while managing dilution, debt restrictions, and the uncertainty of a novel biomaterials market.
- Going-concern and liquidity shortfallImpact: CriticalLikelihood: High
The company stated its cash on hand is insufficient to complete its business plan and that additional financing is required.
Exposure: Operations and continuity of development programs
- Financing dilution and restrictive capital termsImpact: HighLikelihood: High
The company expects to fund operations through debt or equity, which can dilute shareholders or impose operating restrictions.
Exposure - Commercialization and scale-up failureImpact: HighLikelihood: High
The business depends on converting R&D into scalable production and customer adoption, which is unproven at meaningful scale.
Exposure - Dependence on collaborative partners and contractorsImpact: MediumLikelihood: Low
The company plans to use external partners and overseas contractors, which can create quality, timing, and control risks.
Exposure: Manufacturing and product testing
Accounting
Judgemental itemsManagement disclosed substantial doubt about continuing as a going concern, which affects asset recoverability and liability classification assumptions.
Impact: May influence valuation, liquidity analysis, and financial statement presentation
The company issued stock and warrants to employees, consultants, and investors, creating noncash expenses and dilution effects.
Impact: Affects operating expenses, equity, and per-share dilution
The company recorded unrealized appreciation on investment in gold bullion, which can create volatility unrelated to core operations.
Impact: Impacts other income and net loss
Operating lease right-of-use assets and liabilities were referenced in cash flow adjustments and can affect balance sheet leverage.
Impact: Affects assets, liabilities, and operating cash flow reconciliation
Similar listed companies
Publicly listed companies with a comparable business focus.
Nkarta, Inc.
NKTX · Pharmaceutical Preparations
Mosaic ImmunoEngineering Inc.
CPMV · Biological Products, (No Diagnostic Substances)
Pliant Therapeutics, Inc
PLRX · Pharmaceutical Preparations
Pliant Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics.
Cryoport, Inc.
CYRX · Pharmaceutical Preparations
Vir Biotechnology, Inc.
VIR · Biological Products, (No Diagnostic Substances)
Fulgent Genetics, Inc.
FLGT · Services-Medical Laboratories
Last updated: 24/09/2026